Loading...
Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary.
Singh, S Carnaghi, C Buzzoni, R Pommier, R Raderer, M Tomasek, J Lahner, H Voi, M Bubuteishvili-Pacaud, L
Singh, S
Carnaghi, C
Buzzoni, R
Pommier, R
Raderer, M
Tomasek, J
Lahner, H
Voi, M
Bubuteishvili-Pacaud, L
Citations
Altmetric:
Abstract
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin.
Affiliation
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 1.42 MB
Keywords
Type
Article
Citation
Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. 2018, 106(3): 211-220 Neuroendocrinology